Tranexamic Acid to Reduce Contraceptive-related Bleeding Side Effects

Summary

This randomized double blinded trial seeks to determine whether tranexamic acid (TXA) is an efficacious treatment for contraceptive induced menstrual changes (CIMC) including irregular, bothersome bleeding caused by the etonogestrel subdermal contraceptive implant (ENG implant). Participants will be randomized into the TXA treatment arm or a placebo. They will begin taking the medication after three consecutive days of bleeding. Participants will track their bleeding using an automated text message service

Timeline

Start

2024-01-23

Primary completion

2025-08-13

Completion

2025-08-14

Drugs

Indications